Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: The Australian Launch of ProIBS® is on track for Q4 of calendar year 2025 IMM-986 Pre-Clinical Progress: Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci (V
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company's commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub - bringing content and communication into a single integrated platform. The Company will also be regularly uploading new content via the hub, including videos accompanying select announcements, educational material, interview
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high